IL－2和LAK细胞过继免疫疗法在肾癌的应用  

IL-2 and LAK adoptive immunotherapy for renal cell carcinoma

作　　者：张思孝[1] 程鸿鸣[1] 张卫东[1] 李虹[1] 李克[1] 徐刚[1] 张文庚[1] 王艳萍[1] 

机构地区：[1]华西医科大学第一临床学院泌尿外科

出　　处：《中华泌尿外科杂志》1996年第1期48-50,共3页Chinese Journal of Urology

摘　　要：１９９２～１９９３年用ＩＬ－２和ＬＡＫ细胞输注治疗肾细胞癌１４例，全组Ｔ（２～４）期者１１例，５例有远处转移。治疗后获２２个月以上随访，除４例死亡外余尚存活。认为过继免疫疗法对中、晚期肾癌有一定效果，但ＬＡＫ细胞在体内聚集、活化、归转、监测等问题，尚需继续探讨。From Feb.1992 to Mar.1993,systemic administration of autologous lymphokine-activated killer(LAK)cells and recombinant interleukin-2(IL-2)was carried out for 14 cases of renal cell carcinoma,among which 11 were T2～4 with far metastasis already occurred in 5.All the patients have been followed up for more than 22 months,4 died of the disease while the other 10 have been surviving.The result has been encouraging.

关 键 词：肾肿瘤 免疫疗法 白细胞介素2 LAK细胞 

分 类 号：R737.110.5[医药卫生—肿瘤] R730.51[医药卫生—临床医学]